1383452-59-2

Upstream product

• 709-63-7 1-(4-trifluoromethylphenyl)ethanone 
• 1383452-48-9 5-{3-[4-(trifluoromethyl)-phenyl]-1-methyl-1H-pyrazole-5-yl}-1,3,4-oxadiazole-2-thione 
• 1383452-47-8 1-methyl-3-[4-(trifluoromethyl)phenyl]-1H-pyrazole-5-carbohydrazide 
• 93618-49-6 methyl 1-methyl-3-[4-(trifluoromethyl)phenyl]-1H-pyrazole-5-carboxylate 
• 1383452-43-4 sodium (Z)-3-methoxycarbonyl-3-oxo-1-(4-trifluoromethyl)phenyl-propen-1-olate 

Relevant academic research and scientific papers

Design, synthesis and biological evaluation of a novel series of 1,3,4-oxadiazole bearing N-methyl-4-(trifluoromethyl)phenyl pyrazole moiety as cytotoxic agents

On account of the reported anticancer activity of pyrazoles and oxadiazoles, we have designed and synthesized a novel combinatorial library of S-substituted-1,3,4-oxadiazole bearing N-methyl-4-(trifluoromethyl)phenyl pyrazole moiety and tested for in-vitro cytotoxic activity by MTT assay. Amongst the tested compounds, the compound 5e was the most promising anticancer agent with IC50 value of 15.54 μM in MCF-7 cells, compared to Doxorubicin as standard drug. The newly synthesized compounds were characterized by NOE, IR, 1H NMR, 13C NMR and LC-MS analysis.